These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 12033380

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers.
    Zhang Y, Benet LZ.
    Pharm Res; 1998 Oct; 15(10):1520-4. PubMed ID: 9794492
    [Abstract] [Full Text] [Related]

  • 4. Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis.
    Beringer PM, Kriengkauykiat J, Zhang X, Hidayat L, Liu S, Louie S, Synold T, Burckart GJ, Rao PA, Shapiro B, Gill M.
    Pharmacotherapy; 2008 Jul; 28(7):883-94. PubMed ID: 18576903
    [Abstract] [Full Text] [Related]

  • 5. Screening novel CNS drug candidates for P-glycoprotein interactions using the cell line iP-gp: In vitro efflux ratios from iP-gp and MDCK-MDR1 monolayers compared to brain distribution data from mice.
    Ozgür B, Saaby L, Janfelt C, Langthaler K, Eneberg E, Jacobsen AM, Badolo L, Montanari D, Brodin B.
    Eur J Pharm Biopharm; 2021 Dec; 169():211-219. PubMed ID: 34756975
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Transfected MDCK cell line with enhanced expression of CYP3A4 and P-glycoprotein as a model to study their role in drug transport and metabolism.
    Kwatra D, Budda B, Vadlapudi AD, Vadlapatla RK, Pal D, Mitra AK.
    Mol Pharm; 2012 Jul 02; 9(7):1877-86. PubMed ID: 22676443
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate.
    Tolle-Sander S, Rautio J, Wring S, Polli JW, Polli JE.
    Pharm Res; 2003 May 02; 20(5):757-64. PubMed ID: 12751631
    [Abstract] [Full Text] [Related]

  • 13. Improvement of Transmembrane Transport Mechanism Study of Imperatorin on P-Glycoprotein-Mediated Drug Transport.
    Liao ZG, Tang T, Guan XJ, Dong W, Zhang J, Zhao GW, Yang M, Liang XL.
    Molecules; 2016 Nov 24; 21(12):. PubMed ID: 27886150
    [Abstract] [Full Text] [Related]

  • 14. P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin.
    Lagas JS, Sparidans RW, van Waterschoot RA, Wagenaar E, Beijnen JH, Schinkel AH.
    Antimicrob Agents Chemother; 2008 Mar 24; 52(3):1034-9. PubMed ID: 18195061
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs.
    Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K.
    Biol Pharm Bull; 1999 Dec 24; 22(12):1355-9. PubMed ID: 10746169
    [Abstract] [Full Text] [Related]

  • 19. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
    Cummins CL, Jacobsen W, Benet LZ.
    J Pharmacol Exp Ther; 2002 Mar 24; 300(3):1036-45. PubMed ID: 11861813
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.